International Clinical Trial: A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115550) titled 'A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma' on Aug. 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Huai'an First People's Hospital

Condition: Hepatocellular Carcinoma (HCC)

Intervention: Drug: Iparomlimab and Tuvonralimab Injection (QL1706) in combination with Regorafenib

Recruitment Status: Not recruiting

Phase: N/A

Date of F...